Contribution of TRPV1 to Microglia-Derived IL-6 and NFκB Translocation with Elevated Hydrostatic Pressure

Rebecca M. Sappington and David J. Calkins

PURPOSE. The authors investigated the contributions of the transient receptor potential vanilloid-1 receptor (TRPV1) and Ca\(^{2+}\) to microglial IL-6 and nuclear factor kappa B (NFκB) translocation with elevated hydrostatic pressure.

METHODS. The authors first examined IL-6 colocalization with the microglia marker Iba-1 in the DBA/2 mouse model of glaucoma to establish relevance. They isolated microglia from rat retina and maintained them at ambient or elevated (+70 mm Hg) hydrostatic pressure in vitro and used ELISA and immunocytochemistry to measure changes in the IL-6 concentration and NFκB translocation induced by the Ca\(^{2+}\) chelator EGTA, the broad-spectrum Ca\(^{2+}\) channel inhibitor ruthenium red, and the TRPV1 antagonist iodo-resiniferatoxin (I-RTX). They applied the Ca\(^{2+}\) dye Fluo-4 AM to measure changes in intracellular Ca\(^{2+}\) at elevated pressure induced by I-RTX and confirmed TRPV1 expression in microglia using PCR and immunocytochemistry.

RESULTS. In DBA/2 retina, elevated intraocular pressure increased microglial IL-6 in the ganglion cell layer. Elevated hydrostatic pressure (24 hours) increased microglial IL-6 release, cytosolic NFκB, and NFκB translocation in vitro. These effects were reduced substantially by EGTA and ruthenium red. Antagonism of TRPV1 in microglia partially inhibited pressure-induced increases in IL-6 release and NFκB translocation. Brief elevated pressure (1 hour) induced a significant increase in microglial intracellular Ca\(^{2+}\) that was partially attenuated by TRPV1 antagonism.

CONCLUSIONS. Elevated pressure induces an influx of extracellular Ca\(^{2+}\) in retinal microglia that precedes the activation of NFκB and the subsequent production and release of IL-6 and is at least partially dependent on the activation of TRPV1 and other ruthenium red-sensitive channels. (Invest Ophthalmol Vis Sci. 2008;49:3004–3017) DOI:10.1167/iovs.07-1355

Glaucoma is a common optic neuropathy characterized by progressive loss of retinal ganglion cells (RGCs) and is often associated with increases in intraocular pressure.1-3 Although pathologic changes in the physiology of RGCs and their axons, which comprise the optic nerve, are primarily responsible for vision loss in glaucoma, other ocular cell types have also emerged as contributors to the disease process. In particular, astrocyte glia and microglia have been associated with various aspects of glaucoma. These include biochemical and structural changes in the optic nerve head, vascular pathology, and direct modulation of RGC survival.4-20 The contribution of glia to these events is often attributable to a change in the production or release of secreted factors. Increases in the level of inflammatory cytokines, such as tumor necrosis alpha (TNFα), interleukin (IL)-6, interferon gamma (IFNγ), II-1α, II-1β, II-8, and II-10, are evident in plasma and cerebral spinal fluid from a number of optic neuropathies, including neuromyelitis optica,21 optic neuritis,22 and AIDS-related optic neuropathy.23 Similarly, levels of IL-6 in the aqueous humor of patients with neovascular glaucoma are markedly increased.24 Growing evidence suggests that astrocyte glia and microglia produce these cytokines in glaucomatous optic neuropathy and AIDS-related optic neuropathy.4,7-23 Experimental models using elevated pressure or ischemic conditions reveal that many extracellular factors, including TNFα,4,5 nitric oxide,6 and IL-6,13,14,25,26 are released by astrocytes and microglia and can alter RGC survival.

We recently identified IL-6 as a key component of pressure-induced signals from retinal microglia and described its protective properties for RGCs exposed to elevated pressure.13 We further identified the ubiquitin–proteasome pathway and activation of the transcription factor nuclear factor kappa B (NFκB), which are responsible for the production of IL-6 by astrocytes, microglia, and macrophages in other systems.27-37 As components of the pressure-induced release of IL-6,14 In other systems, the influx of extracellular Ca\(^{2+}\) can induce IL-6 production through the activation of NFκB,58-41 including that induced by cellular stretch.42 In microglia, Ca\(^{2+}\) mediates the response to a number of stimuli, including the activation of purinergic receptors, glutamate, and various proinflammatory cytokines.3 Here, to probe its relevance to glaucoma, we found that microglia-derived IL-6 increases with elevated intraocular pressure (IOP) in the DBA/2 mouse model of hereditary glaucoma. To probe the mechanisms of IL-6 release in vitro, we describe the influence of Ca\(^{2+}\) chelation and of blocking Ca\(^{2+}\) channels on pressure-induced activation of NFκB and subsequent IL-6 release by retinal microglia. We also describe the novel finding that retinal microglia, like microglia in the brain and spinal cord,44,45 express the capsaicin-sensitive, cation-selective receptor potential vanilloid-1 receptor (TRPV1). Using a hydrostatic pressure chamber, we determined that extracellular Ca\(^{2+}\) is required for pressure-induced IL-6 release and activation of NFκB in primary cultures of retinal microglia. Broad antagonism of vanilloid receptors and of TRPV1 with ruthenium red also inhibited IL-6 release and NFκB activation, though less efficiently. Specific antagonism of TRPV1 with iodo-resiniferatoxin (I-RTX; Alexis Biochemicals, Lausen, Switzerland) partially reduced the pressure-induced IL-6 release and activation of NFκB and the pressure-induced increases in intracellular Ca\(^{2+}\). Interestingly, the activation of TRPV1 alone, with its agonist capsaicin, was not sufficient to increase IL-6 concentration. Together these data suggest that elevated hydrostatic pressure induces an influx of extracellular Ca\(^{2+}\) in retinal microglia that precedes the activation of NFκB and the subsequent production and release of IL-6.
This influx is mediated in part by the activation of TRPV1, though other pressure-induced events are necessary to promote increases in IL-6 release.

**Materials and Methods**

**Animals and Tissue Preparation**

This study was conducted in accordance with regulations set forth in the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Animal protocols were approved by the Institutional Animal Care and Use Committee of the Vanderbilt University Medical Center. For DBA/2 studies, paraformaldehyde (4%)-fixed whole eyes from 6-month-old DBA/2 mice with relatively low (average, 14.7 mm Hg) or higher (average, 21.2 mm Hg) IOP were obtained from Brown University (Providence, RI) and were prepared for immunolabeling as whole mount specimens. As previously described, IOP was monitored monthly with a tonometer (Tono-Pen; Reichert, Depeg, NY) before kill. 45 For histology, adult Sprague–Dawley rats (Charles River Laboratories, Wilmington, MA) were perfused with 4% paraformaldehyde (Sigma, St. Louis, MO), their eyes were enucleated, and their retinas were dissected, as previously described.13,14

**Cell Separation and Primary Culture**

Primary cultures of purified retinal microglia were prepared as we previously described and published in this journal.13,14 Briefly, retinas from P4 to P10 Sprague–Dawley rats were dissociated by trituration and incubation at 37°C in 1 mg/mL papain + 0.005% DNase I (Worthington, Lakewood, NJ). Viability was assessed by trypan blue exclusion. To purify microglia, the cells were incubated in monoclonal anti-mouse OX18 antibody (5 μg/mL; catalog number CBL1519; Chemicon, Temecula, CA) or monoclonal anti-rat OX18 antibody (8 μg/mL; catalog number MCA51R; AbD Serotec, Raleigh, NC) followed by incubation with a magnetic bead-conjugated secondary antibody (Miltenyi Biotec, Auburn, CA). The cells were then loaded into a prequadruplicate column in the presence of a magnetic field (Miltenyi Biotec). Cells positively selected by the anti-OX18 antibody were eluted, plated at a density of 5 × 10⁴ on two-chamber glass slides or 1 × 10⁴ on eight-chamber glass slides (Nalge-Nunc, Rochester, NY), and maintained in a 50:50 mixture of Dulbecco modified Eagle medium and F12 medium (DMEM/F12; Invitrogen, Carlsbad, CA) plus supplements. Cultures were grown to approximately 80% confluence (10–14 days) in a standard incubator with 5% CO₂ before our timed experiments. During this time, 50% of the culture media were replaced every 48 hours. As previously reported, the purity of our microglial cultures was determined by positive immunolabeling and PCR reactions for microglia-specific markers (OX18 and CD68) and by negative results for markers against astrocytes, Müller glia, and fibroblasts. 13 Culture media to produce the following final concentrations: 950 μM ethylene glycol bis(benzyloxyethyl)N,N,N′,N′-tetra-acetic acid (EGTA; Invitrogen), 13,14 0.7 μM, 7 μM, or 70 μM ruthenium red (Calbiochem, San Diego, CA), 0.1 μM, 1 μM, or 10 μM IRTX (Alexis Biochemicals), and 1 μM capsaicin (Sigma). 41-50 Stock solutions were prepared as follows: 100 mM EGTA in NaOH-buffered ddH₂O, 10 mM ruthenium red in ddH₂O, 10 mM IRTX in dimethyl sulfoxide (DMSO), and 10 mM capsaicin in ethanol. Our calculations predict that 950 μM EGTA reduced the concentration of free Ca²⁺ in the media from 1 mM to 100 μM, as determined (Max Chelator; Stanford University, Stanford, CA). This dose was chosen to maximally chelate extracellular Ca²⁺ while avoiding the disruption of cell adhesion. 51-57 Control cultures for pharmacology studies were treated with an equivalent volume of the vehicle(s) sterile H₂O (EGTA and ruthenium red), DMSO (IRTX), or ETOH (capsaicin).

**Enzyme-Linked Immunoabsorbent Assay**

We used ELISA to measure the concentration of IL-6 secreted by microglia in response to elevated pressure and capsaicin. The culture media were prepared for analysis, and ELISA assays were performed, as previously described. 13,14 Briefly, the media were first centrifuged at low speed to remove intact cells and were centrifuged again at a high speed to remove cellular debris. ELISA was conducted with anti-rat IL-6 ELISA kits (R&D Systems, Minneapolis, MN) according to manufacturer’s recommendations. Each sample well was run in duplicate, thus providing six total measurements per condition. The concentration of IL-6 in each sample was determined by a comparison of the optical densities in the sample wells to that of the standard curve (Molecular Devices, Sunnyvale, CA). To determine the sensitivity of the IL-6 ELISA kit, we calculated the minimal concentration of cytokine necessary for detection. Based on the experimental optical density values, we performed a back calculation of cytokine concentration for the zero standards in 14 separate assays. These concentrations were averaged, and the standard deviation was multiplied by 2 to obtain a minimum reliable detection of 2.3983 pg/mL.

**Calcium Signaling Experiments**

To assess pressure-induced changes in intracellular Ca²⁺, we used the Ca²⁺-dye Fluoro-AM (Molecular Probes, Eugene, OR). This dye is closely related to Fluo-3, which has been used in many studies for live Ca²⁺ imaging and for measuring Ca²⁺ accumulation. 58-60 Fluoro-4 is a BAPTA-based, non-ratiometric Ca²⁺-dye that exhibits more than a 40-fold increase in fluorescence with Ca²⁺ binding. 64 Although changes in Ca²⁺ signaling are apparent within milliseconds for many stimuli, we were interested in longer changes in intracellular Ca²⁺ that could lead to a sustained cellular event, such as pressure-induced production and release of IL-6 in retinal microglia. 13 Thus, we chose to examine Fluoro-4 label after exposure to the stimulus for 1 hour, consistent with the period for reliable detection and interpretation of Fluoro-4 label. 64 To allow complete de-esterification of Fluoro-AM, primary microglia cultures were loaded with 5 μM Fluoro-AM for 30 minutes in a standard culture incubator. The media were replaced, and the cultures were examined to confirm comparable Fluoro-4 loading. When this was complete, the cultures were segregated into control and experimental groups. The experimental group was exposed to +70 mm Hg hydrostatic pressure in our specialized chamber for 1 hour, and the control group was maintained in a standard culture incubator. Immediately after the experiment, the live cultures were coveredslipped with physiological saline and imaged on the microscope. For each sample, 15 to 20 independent fields (20 ×) were acquired, surface plots were created, and Fluoro-4 intensity was quantified as total fluorescent intensity across the field.

**Statistical Analysis**

For comparison of ELISA data between treatment groups, we compared the mean concentration of IL-6 from a minimum of three sepa-
rate experiments with the Student's t-test, where \( P < 0.05 \) was considered statistically significant. For comparison of Flu-o-i data between treatment groups, we compared the mean total intensity from a minimum of three separate experiments, which included 15 to 20 measurements each, with the Student's t-test, where \( P < 0.05 \) was considered statistically significant. All data are reported as mean ± SE.

### Immunohistochemistry

For IL-6 and TRPV1 colocalization studies, immunolabeling in whole mount retina was performed as previously described, with the addition of heat-mediated antigen retrieval (10 mM citrate buffer, pH 6.0) for the microglial marker Iba-1.\(^{13,14,65,66} \) For IL-6 studies, immunolabeling was performed with rabbit anti-IL-6 IgG (1:400; catalog number ab6672; Abcam, Cambridge MA) and goat anti-Iba-1 (1:400; catalog number ab5076; Abcam) and were visualized with donkey anti-rabbit IgG conjugated to an Alexa 488 fluorophore (10 \( \mu \)g/mL; Molecular Probes) and donkey anti-goat IgG conjugated to an Alexa 594 fluorophore (10 \( \mu \)g/mL; Molecular Probes). For TRPV1, immunolabeling was performed with rabbit anti-TRPV1 (1:100; catalog number NB100-1617; Novus Biologicals, Littleton, CO) and mouse anti–Iba-1 (1 \( \mu \)g/mL; Abcam) and was visualized with goat anti-mouse IgG conjugated to an Alexa 594 fluorophore (10 \( \mu \)g/mL; Molecular Probes) and goat anti-rabbit IgG conjugated to an Alexa 488 fluorophore (10 \( \mu \)g/mL; Molecular Probes). Controls for immunohistochemistry experiments were conducted with no primary antibody and the appropriate IgG isotypes.

### Immunocytochemistry

Immunolabeling in primary cultures of microglia cultures and whole mount preparations of rat retina was performed with slight modification, as previously described.\(^{13,14,65,66} \) For NFkB translocation studies, immunolabeling was performed with mouse anti-NFkB p65 subunit (1 \( \mu \)g/mL; BD PharMingen, San Diego, CA) and was visualized with goat anti-mouse IgG conjugated with Alexa 488 fluorophore (10 \( \mu \)g/mL; Molecular Probes). Samples were also counterstained with the nuclear dye DAPI (50 \( \mu \)g/mL; Molecular Probes). Controls for ICC experiments were conducted with no primary antibody and the appropriate IgG isotypes.

### Fluorescence Microscopy

NFkB immunolabeling, TRPV1 immunolabeling, and Flu-o-i labeling in primary cultures of retinal microglia cultures were examined with an upright microscope equipped with differential interference contrast (DIC), a fluorescent lamp, and four wavelength cubes (Olympus, Melville, NY) digitally interfaced with cooled camera and image capture software (Diagnostic Instruments, Sterling Heights, MI). Imaging of immunolabeling in whole mount retina against IL-6 + Iba-1 and TRPV1 + Iba-1 was performed at the Vanderbilt Cell Imaging Core on an upright confocal microscope (LSM510 META; Zeiss, Thornwood, NY) equipped with laser scanning fluorescence (blue/green, red, red/or) and Nomarski-DIC, 3D–series, and time-series. All samples were examined with a 63× oil-immersion objective (1.40; Plan-Apochromat; Zeiss), and images were acquired with a digital camera (AxioCam HR; Zeiss) and image analysis software (LSM 5; Zeiss).

### Reverse Transcription–Polymerase Chain Reaction

Total RNA was isolated, according to the manufacturer's instructions, from isolated microglia and whole retina using extraction kits (MicroRNA and RNeasy; Qiagen, Inc., Valencia, CA). RT-PCR was performed as previously described.\(^{13,14,65,66} \) After first- and second-strand synthesis of cDNA, gene-specific PCR was conducted for 50 cycles with primers against rat trpv1 that were designed to span an intron (Integrated DNA Technologies, Coralville, IA): 5’-CAAGGACAAGATGATCGTCC3’ and 5’-CACTTCCACACCATTCGCC3’. The resultant PCR product of 282 bp was separated on an agarose gel stained with ethidium bromide

and digitally imaged on a gel reader (Alpha Innotech, San Leandro, CA). To ensure that resultant bands were not the product of contamination with genomic DNA, gene-specific PCR without reverse transcription was performed on RNA samples from each culture.

### Results

**Microglia-Derived IL-6 in the DBA/2 Mouse Model of Glaucoma**

We have previously shown that primary cultures of purified microglia increase the production and release of IL-6 in response to elevated hydrostatic pressure.\(^{13,14,65,66} \) This microglia-derived IL-6 can increase the survival of RGCs also exposed to elevated hydrostatic pressure.\(^{13} \) To test whether microglia-derived IL-6 could be relevant in vivo, we examined the colocalization of IL-6 and the microglia marker Iba-1 in whole mount preparations of retina from 6-month-old DBA/2 mice with relatively low IOP (average, 14.7 mm Hg) and higher IOP (average, 21.2 mm Hg). The DBA/2 mouse is a model of pigmentary glaucoma in which iris stromal atrophy and iris pigment dispersion, caused by mutations in the Tyrp1 and Gpnmb genes, lead to elevated IOP that rises significantly across the population between 6 and 9 months of age.\(^{67,68} \) In DBA/2 mice with relatively low IOP, IL-6 was present at levels just detectable in the extracellular space within the ganglion cell layer (Fig. 1A), and Iba-1 labeling identified the presence of microglia in the same plane (Fig. 1B). A direct comparison of the two markers revealed IL-6 within microglia cell bodies and processes (Fig. 1C); this is shown at higher magnification in Figure 1G. In contrast, retinas from DBA/2 mice with higher IOP demonstrated marked increases in labeling for IL-6 in the ganglion cell layer (Fig. 1D), again especially in the extracellular space surrounding RGCs and in what appeared to be microglial processes. This was confirmed with labeling against Iba-1 (Fig. 1E), which also revealed hypertrophy and increased ramification of microglia. A direct comparison of IL-6 and Iba-1 showed strong colocalization (Fig. 1F) that was even more apparent at high magnification (Fig. 1H), suggesting that microglia are a source of the elevated extracellular IL-6. We also noted IL-6 labeling in cells on the superficial surface of the nerve fiber layer (data not shown); these exhibited morphology consistent with astrocytes, suggesting another source of IL-6. Together, these data confirm that elevated IOP, like elevated hydrostatic pressure, increases microglial IL-6. Furthermore, the presence of IL-6 in the extracellular space surrounding RGCs suggests that RGCs are a likely target for an IL-6 signal.

**Pressure-Induced IL-6 Release, NFκB Translocation, and Extracellular Ca\(^{2+}\)**

To continue our examination of mechanisms that underlie the pressure-induced production and release of IL-6 by microglia, we tested whether extracellular Ca\(^{2+}\) contributes to the pressure-induced release of IL-6 from retinal microglia, as it does in other cells.\(^{38-31} \) We maintained isolated microglia for 24 hours at either ambient or +70 mm Hg hydrostatic pressure after chelation of extracellular Ca\(^{2+}\) with 950 \( \mu \)g/mL EGTA, which reduced the concentration of free Ca\(^{2+}\) in the media from 1 mM to 100 \( \mu \)M (see Materials and Methods). We then measured the concentration of IL-6 in the culture media using ELISA. Consistent with our previous findings, IL-6 secretion from microglia at ambient pressure was relatively low (135 ± 7.5 pg/mL; Fig. 2). Treatment with EGTA slightly increased the concentration of IL-6 to 196 ± 9.4 pg/mL, a significant departure from ambient pressure alone (\( P = 0.02; \) Fig. 2). Also consistent with our previous findings, exposure to elevated pressure induced an almost 10-fold increase in IL-6 concentra-
FIGURE 1. IL-6 Increases with elevated IOP in the DBA/2 mouse model of glaucoma. Confocal micrographs through the ganglion cell layer of 6-month-old DBA/2 retinas immunolabeled for IL-6 and the microglia-specific marker Iba-1. Retina from eyes with relatively low IOP (average, 14.7 mm Hg; A–C) or higher IOP (average, 21.2 mm Hg; D–F). (A) Modest level of extracellular IL-6 in the ganglion cell layer of a retina with low IOP. (B) Several microglia in the same focal plane labeled by Iba-1. (C) Overlay of IL-6 and Iba1 reveals a low level of colocalization (yellow) associated mainly with microglial processes. (D) Stronger IL-6 labeling in retina with elevated IOP is concentrated in the extracellular space surrounding RGC cell bodies (arrows) and in cellular processes near RGCs (arrowbeads). (E) Iba-1 labeling in the same field reveals hypertrophic microglial processes and an increase in ramifications (compare with B). (F) Overlay reveals increased colocalization (yellow) of IL-6 and Iba-1, primarily in the processes of microglia. Scale is the same for (A–F). (G) Higher magnification of Iba-1 and IL-6 labeling shown in (C) demonstrates colocalization in microglia cell bodies (arrowbeads) and processes (arrows). (H) Higher magnification of (F) reveals even stronger colocalization with increased IOP. Microglia cell bodies are indicated (arrowbeads). Scale is the same for (G, H).

FIGURE 2. Chelation of extracellular Ca^{2+} inhibits pressure-induced IL-6 release by retinal microglia. ELISA measurements of IL-6 concentration in the culture media of primary retinal microglia exposed to ambient or elevated pressure for 24 hours in the presence or absence of the Ca^{2+} chelator EGTA (950 µM). *P < 0.05 compared with ambient pressure alone. †P < 0.05 compared with elevated pressure alone. n = 4 per condition.

Pressure-induced microglial release of IL-6, like that of IL-6 induced by other stimuli, arises significantly from de novo synthesis mediated by upstream activation of the transcription factor NFκB. This activation is early and sustained; translocation is evident within 8 hours of exposure and is maintained for more than 72 hours. To determine whether the observed effects of chelating extracellular Ca^{2+} on IL-6 release could arise by modulation of this transcriptional event, we examined the nuclear translocation of NFκB after the same exposure to elevated pressure, again in the presence or absence of EGTA. Consistent with our published results, at ambient pressure NFκB in microglia was localized exclusively to the cytosol, as determined by comparing p65 immunolabeling for NFκB with the nuclear counterstain DAPI (Fig. 3A). Chelation of extracellular Ca^{2+} with EGTA at ambient pressure induced a minute increase in nuclear labeling of NFκB (Fig. 3B). This should be compared with the slight increase in IL-6 at ambient pressure with EGTA, as measured by ELISA (Fig. 2).
Consistent with our earlier findings, exposure to elevated pressure increased the intensity of cytosolic labeling and also induced significant translocation to the nucleus (Fig. 3C). In contrast, Ca\(^{2+}\) chelation with EGTA at elevated pressure significantly decreased the intensity of nuclear labeling and overall cytosolic levels of NF\(_{\kappa}B\) (Fig. 3D). Treatment with EGTA appeared to have qualitatively altered the shape of nuclei in our microglia cultures. However, an analysis of nuclei size revealed no statistical difference between the treatment groups (data not shown). These results suggest that, like IL-6 release, extracellular Ca\(^{2+}\) could differentially regulate the translocation of NF\(_{\kappa}B\), depending on pressure, promoting translocation at elevated pressure (compare Figs. 3C and 3D) while potentially attenuating translocation at ambient pressure (compare Figs. 3A and 3B).

**Pressure-Induced IL-6 Release, NF\(_{\kappa}B\) Translocation, and Ca\(^{2+}\) Channels**

To begin the task of identifying Ca\(^{2+}\) channels that may contribute to the Ca\(^{2+}\)-dependent release of IL-6 and the translocation of NF\(_{\kappa}B\), we maintained microglia at ambient or elevated pressure for 24 hours in the presence or absence of the broad-spectrum Ca\(^{2+}\) channel antagonist ruthenium red (0.7–70 \(\mu\)M) and again assessed IL-6 with ELISA and translocation of NF\(_{\kappa}B\) with immunocytochemical labeling. We chose ruthenium red (IC\(_{50}\) 7 \(\mu\)M) as our initial antagonist because of its ability to inhibit ryanodine-sensitive channels and TRPV1,69–75 which are both reported to modulate Ca\(^{2+}\) activity in microglia.44,76,77

In microglia cultures maintained at ambient pressure, treatment with ruthenium red did not significantly alter the basal concentration of IL-6 in the culture media (\(P > 0.05\) for all; Fig. 4). In contrast, ruthenium red altered the pressure-induced release of IL-6 in a dose-dependent manner. At our lowest concentration (0.7 \(\mu\)M), ruthenium red actually increased the concentration of IL-6 in the culture media at elevated pressure by 22% (1647 ± 157.8 pg/ml) compared with elevated pressure alone (\(P < 0.01\); Fig. 4). This increase was reversed at the median IC\(_{50}\) concentration (7 \(\mu\)M) and at the highest concentration (70 \(\mu\)M), which decreased IL-6 concentrations at elevated pressure by 28% (920 ± 106.3 pg/ml; \(P < 0.01\)) and 57% (804 ± 143 pg/ml; \(P < 0.05\)), respectively (Fig. 4). These data suggest that the pressure-induced release of IL-6 by retinal microglia is at least partially regulated by Ca\(^{2+}\) flux through channels sensitive to ruthenium red.

As in the IL-6 studies, treatment with ruthenium red at all concentrations did not alter the levels or localization of NF\(_{\kappa}B\) at ambient pressure, which was almost exclusively cytosolic (Figs. 5A–D). Like IL-6 release, the effects of ruthenium red on the translocation of NF\(_{\kappa}B\) at elevated pressure were dose dependent. In agreement with the observed effect on IL-6 release (Fig. 4), treatment with 0.7 \(\mu\)M ruthenium red did not significantly change pressure-induced translocation of NF\(_{\kappa}B\) to the nucleus (compare Figs. 5E and 5F). In contrast, treatment with 7 \(\mu\)M (Fig. 5G) and 70 \(\mu\)M ruthenium red (Fig. 5H) greatly diminished the translocation of NF\(_{\kappa}B\), as seen by decreased colocalization of p65 label with the DAPI nuclear stain. These

![Figure 3](http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932952/ on 06/24/2017)

**Figure 3.** Chelation of extracellular Ca\(^{2+}\) inhibits the translocation of NF\(_{\kappa}B\) in retinal microglia. Primary cultures of retinal microglia exposed to ambient or elevated pressure for 24 hours alone (A, C) or with the Ca\(^{2+}\) chelator EGTA (950 \(\mu\)M; B, D). (A) Fluoromicrograph of immunolabeling against the p65 subunit of NF\(_{\kappa}B\) (green) with nuclear counterstain DAPI (blue) at ambient pressure. With EGTA treatment (B), there is a very slight increased incidence of colocalization of NF\(_{\kappa}B\) with DAPI (arrows). (C) Elevated pressure induces increased cytosolic NF\(_{\kappa}B\) and nuclear translocation, as seen by strong colocalization with DAPI (arrows). (D) Treatment with EGTA reduces cytosolic NF\(_{\kappa}B\) and nuclear translocation, as seen by decreased colocalization with DAPI (arrowheads).

![Figure 4](http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932952/ on 06/24/2017)

**Figure 4.** Treatment with ruthenium red inhibits pressure-induced IL-6 release in retinal microglia. ELISA measurements of the IL-6 in culture media of primary retinal microglia exposed to ambient (left) or elevated (right) pressure for 24 hours in the presence or absence of the broad-spectrum Ca\(^{2+}\) channel inhibitor ruthenium red (RR; 0.7–70 \(\mu\)M). *\(P < 0.05\) compared with ambient pressure alone. †\(P = 0.05\) compared with elevated pressure alone. \(n = 3\) per condition.
concentrations were also accompanied by a decrease in the intensity of cytosolic labeling of NFκB, compared with treatment with 0.7 µM ruthenium red (Fig. 5F). These data suggest that, like the Ca\(^{2+}\)-dependent release of IL-6, nuclear translocation of NFκB in response to elevated pressure is mediated by Ca\(^{2+}\) channels sensitive to ruthenium red. Interestingly, these channels do not appear to regulate the basal release of IL-6 or the translocation of NFκB, as suggested by the absence of a response to ruthenium red in cultures maintained at ambient pressure (Figs. 4, 5A–D).

### Pressure-Induced Release of IL-6, Translocation of NFκB, and TRPV1 Antagonism

Results in Figures 2 and 3 demonstrate that the chelation of extracellular Ca\(^{2+}\) dramatically reduced IL-6 release and NFκB translocation. These data suggest that Ca\(^{2+}\) influx from the extracellular milieu is a likely contributor to pressure-induced effects. Ruthenium red, which inhibits TRPV1 and ryanodine receptors,\(^69–75\) also attenuated pressure-induced IL-6 release and NFκB translocation (Figs. 4, 5). Although TRPV1 is associated with the influx of extracellular Ca\(^{2+}\) and the release of Ca\(^{2+}\) from intracellular stores, ryanodine receptors are exclusively associated with the release of Ca\(^{2+}\) from intracellular stores.\(^78–79\) Thus, we focused next on the potential contribution of TRPV1 to the pressure-induced release of IL-6 and translocation of NFκB.

We exposed primary cultures of retinal microglia to ambient or elevated pressure for 24 hours in the presence of the TRPV1-specific antagonist iodo-resiniferatoxin (I-RTX; 0.1–10 µM). Again, we measured the concentration of IL-6 in the culture media and examined the immunolabeling of p65 NFκB. The median dose of 1 µM was selected from extensive literature in which this dose reliably inhibited TRPV1-dependent behaviors across multiple systems.\(^80–83\) At ambient pressure, treatment with I-RTX did not significantly alter the concentration of IL-6 in the media (P > 0.05 for all; Fig. 6A). In contrast, for microglia exposed to elevated pressure, treatment with I-RTX reduced the concentration of IL-6 in the media. This
effect was dose dependent, where the lowest concentration of I-RTX (0.1 µM) did not significantly alter the concentration of IL-6 (1196 ± 61.3 pg/ml; P = 0.41), and the median and highest doses (1 µM and 10 µM) reduced the media concentration of IL-6 by 25% (954 ± 77.7 pg/ml; P < 0.01) and 26% (939 ± 100 pg/ml; P < 0.01), respectively (Fig. 6A). However, it is important to note that I-RTX did not reduce the concentration of IL-6 to levels observed at ambient pressure. In fact, IL-6 levels remained sevenfold higher than levels at ambient pressure (P < 0.01 for both; Fig. 6A). Consistent with this observation, the pharmacologic activation of TRPV1 with 1 µM capsaicin, a well-established dose for activating TRPV1, did not alter the concentration of IL-6 in the culture media (Fig. 6B). These data suggest that TRPV1 antagonism induces partial inhibition of pressure-induced increases in IL-6 release by microglia. However, the activation of TRPV1 alone is not sufficient to promote IL-6 release.

Despite the moderate effect of I-RTX on pressure-induced increases in the media concentration of IL-6, treatment with I-RTX greatly diminished pressure-induced translocation of NFκB to the nucleus. Consistent with our analysis of IL-6, I-RTX did not appear to alter the pattern of NFκB in cultures maintained at ambient pressure, where NFκB was almost exclusively restricted to the cytosol (Figs. 7A–D). In contrast, the effects of I-RTX on pressure-induced translocation of NFκB and increased cytosolic levels (Fig. 7E) were dose dependent. The 0.1-µM dose of I-RTX slightly reduced the colocalization of NFκB with DAPI, particularly in the center of the nucleus (Fig. 7F). Cytosolic levels were also slightly diminished. The trend toward reduced NFκB translocation and cytosolic levels continued with the median and highest doses of I-RTX (Figs. 7G, 7H), where the 10-µM dose demonstrated the most pronounced separation of p65 label and DAPI (Fig. 7H). Similar to labeling with the highest dose of ruthenium red, the 10-µM dose of I-RTX also reduced most dramatically the intensity of NFκB in the cytosol (compare Figs. 7H and 5H). These data suggest that the antagonism of TRPV1 significantly diminishes the activation and translocation of NFκB in retinal microglia exposed to elevated pressure. Interestingly, the effect of I-RTX on NFκB translocation was far more striking than that observed on levels of IL-6 in media, suggesting that TRPV1 activity may have a greater impact on early signaling events related to the initiation of IL-6 transcription rather than on the actual release of the signaling molecule.

**Elevated Pressure and Microglial Intracellular Ca²⁺**

Figure 2 indicates that the chelation of extracellular Ca²⁺ inhibits the pressure-induced release of IL-6 and the translocation of NFκB, implying that each requires an increase in intracellular Ca²⁺ through influx from the extracellular domain. To determine whether elevated pressure increases intracellular Ca²⁺ in microglia and whether TRPV1 contributes directly to these increases, we measured pressure-induced changes in Fluo-4 AM fluorescence as an indicator of changes in cytosolic Ca²⁺. We examined the localization and intensity of Fluo-4 label in microglia cultures exposed to ambient or elevated pressure for 1 hour in the presence of I-RTX (1 µM). Fluo-4 label in microglia maintained at ambient pressure was low and was restricted to the cell body (Fig. 8A). Exposure to elevated pressure for 1 hour dramatically increased Fluo-4 label in microglia cell bodies and induced an expansion of signal to include processes (Fig. 8B). These differences are readily apparent by comparing the surface rendering of the Fluo-4 signal at ambient pressure with that representing elevated pressure (Figs. 8A, 8B). Specific antagonism of TRPV1 with 1 µM I-RTX greatly reversed most of the pressure-induced increases in Fluo-4 label, particularly in microglial processes (compare Figs. 8C and 8B). In contrast, treatment with I-RTX did not appear to affect the distribution of Fluo-4 label in microglia maintained at ambient pressure (Fig. 8D). Quantification of total signal intensity revealed an overall twofold increase in microglia Ca²⁺ with elevated pressure compared with ambient pressure (P < 0.01; Fig. 8E). This pressure-induced increase was reduced by 26% after treatment with I-RTX (P < 0.01; Fig. 8E). However, treatment with I-RTX did not reduce Fluo-4 levels to those observed at ambient pressure (P = 0.02; Fig. 8E). In contrast, treatment with I-RTX did not alter Fluo-4 label in microglia maintained at ambient pressure (P = 0.47; Fig. 8E). These data...
suggest that the increases in intracellular Ca\(^{2+}\) in retinal microglia caused by exposure to elevated pressure are prolonged in terms of Ca\(^{2+}\) signaling but far precede the pressure-induced translocation of NFkB and increased IL-6 release. Furthermore, these increases arise in part by the activation of TRPV1.

**Expression of TRPV1 in Retinal Microglia**

Finally, we examined the expression of TRPV1 in our microglia cultures and the localization of TRPV1 in microglia of the adult rat retina in situ. TRPV1 in microglia cultures is diffusely distributed throughout the cell body and cellular processes (Fig. 9A). The presence of perinuclear label and the diffuse nature of somal labeling suggests that TRPV1 is most likely present in the endoplasmic reticulum and on the plasma membrane (Fig. 9A).

**FIGURE 8.** Antagonism of TRPV1 attenuates pressure-induced increases in microglia Ca\(^{2+}\) levels. Fluoromicrographs with corresponding surface plots of primary cultures of retinal microglia exposed to ambient or elevated pressure for 1 hour after incubation with the Ca\(^{2+}\) dye Fluo-4 AM. (A) Fluo-4 label is present at very low levels in microglia maintained at ambient pressure (left). A plot of signal distribution reveals Fluo-4 label in what are most likely cell bodies (right). (B) Elevated pressure qualitatively increases Fluo-4 intensity (right) and induces Fluo-4 label in microglial processes (arrows and inset; left). (C) Treatment with I-RTX qualitatively reduces Fluo-4 label in cell bodies and processes (compare C and B). (D) Treatment with I-RTX at ambient pressure does not appear to alter Fluo-4 labeling (compare D and A). Scale is the same for (A–D). (E) Quantification of Fluo-4 label indicates a 54% increase in intensity for microglia exposed to elevated pressure (*). I-RTX treatment reversed this pressure-induced increase in Fluo-4 intensity (*). Symbols indicate P < 0.05; error bars represent SE. Pixel intensity was calculated as the average of total intensity from 15 to 20 independent fields. n = 3 per condition.
suggest that TRPV1 is a viable candidate for further assessment of the contribution to Ca\textsuperscript{2+}-dependent IL-6 release and NF\kappa B translocation in microglia exposed to elevated pressure.

**DISCUSSION**

Our previous work demonstrated that retinal microglia in vitro increase the release of IL-6 in response to elevated hydrostatic pressure and that this increase in IL-6 affords protection against pressure-induced apoptosis in RGCs.\textsuperscript{13,14} Here we provide evidence that microglia-derived IL-6 is a component of IOP-related changes in the DBA/2 retina. We demonstrate that as IOP increases, IL-6 is present at significantly higher levels in the extracellular space surrounding RGCs and within the processes of highly ramified microglia (Fig. 1). Our data suggest that, like elevated hydrostatic pressure, elevated IOP is a stimulus for IL-6 production in microglia in vivo. Furthermore, it is likely that microglia, with both relatively low and relatively high IOP, are a source of the extracellular IL-6 in retina. Together these data validate the potential significance of microglia-derived IL-6 on RGC survival in glaucoma, as suggested by our previous studies.\textsuperscript{13,14}

Mechanistically, we also previously demonstrated that the activation of retinal microglia by elevated hydrostatic pressure involves the activation of NFkB and the subsequent production and release of IL-6.\textsuperscript{13,14} It is known that Ca\textsuperscript{2+} and Ca\textsuperscript{2+} channels mediate the activation of microglia in response to a number of stimuli, such as activated purinergic receptors, glutamate, and various proinflammatory cytokines.\textsuperscript{85} Here we determined that Ca\textsuperscript{2+} is a strong modulator of pressure-induced IL-6 release and NF\kappa B translocation. By chelating extracellular Ca\textsuperscript{2+} with EGTA, we determined that Ca\textsuperscript{2+} plays a role in promoting IL-6 release and NF\kappa B translocation in response to pressure but could attenuate IL-6 and NF\kappa B translocation under ambient conditions (Figs. 2, 3). Interestingly, the effect of Ca\textsuperscript{2+} chelation on the translocation of NF\kappa B appears less significant than that observed with IL-6 release. Furthermore, it is important to note that our dose of EGTA did not reduce IL-6 levels to those measured at ambient pressure. Although a larger dose of EGTA would likely reduce IL-6 levels further, data obtained from such a decrease in available Ca\textsuperscript{2+} could not be interpreted as the result of a specific pathway. Instead, these data would likely have stemmed from global responses to prolonged deficiency in Ca\textsuperscript{2+} (i.e., decreased cell adhesion, inhibition of transcription, and cell death).\textsuperscript{51–57} These data suggest that Ca\textsuperscript{2+} is involved in transcriptional and posttranscriptional events induced by elevated pressure. Although Ca\textsuperscript{2+} is likely to modulate pressure-induced release indirectly through the induction of NF\kappa B translocation, it appears to play a larger role in the direct induction of IL-6. These direct effects could occur at multiple levels of the signaling cascade, including translation, protein trafficking, and release mechanisms. Our data here do not distinguish among these cellular activities, but we are examining them in detail.

Many types of Ca\textsuperscript{2+} channels and transporters are responsible for the regulation of Ca\textsuperscript{2+} signaling. In microglia, ryanodine-sensitive channels and TRPV1 are reported to modulate Ca\textsuperscript{2+} activity that leads to various cellular responses.\textsuperscript{44,77} Using ruthenium red, we examined the contribution of these two subsets of channels to the pressure-induced release of IL-6 and NF\kappa B translocation (Figs. 4, 5). At elevated pressure, treatment with ruthenium red decreased IL-6 release and NF\kappa B translocation at the two highest doses, suggesting that ryanodine-sensitive or TRPV1 channels are involved in regulating Ca\textsuperscript{2+} dependent release of IL-6 and nuclear translocation of NF\kappa B. Interestingly, the lowest dose of ruthenium red (0.7 µM) actually increased pressure-induced IL-6 release and NF\kappa B translocation. Although the exact mechanism of this dose effect is
unclear, it is likely that this effect stems from ruthenium red-induced inhibition of ryanodine-sensitive channels, which are competitively bound by ruthenium red at a dose as low as 0.3 μM.91,92 In contrast to its effects on ryanodine-sensitive channels, ruthenium red is reported to attenuate TRPV1 through noncompetitive binding at doses ranging from 1 μM to 100 μM.93-96 Although the involvement of ruthenium red-sensitive channels in pressure-induced effects is complex, these channels do not appear to modulate the basal release of IL-6 because ruthenium red did not alter IL-6 concentrations or NFκB translocation at ambient pressure.

We further examined the contribution of TRPV1 to pressure-induced IL-6 release and NFκB translocation (Figs. 6, 7). We determined that pharmacologic antagonism of TRPV1 with I-RTX attenuated the pressure-induced release of IL-6, but only by approximately 25%. Of note, the lowest dose of I-RTX did not alter IL-6 concentrations, whereas 1 μM and 10 μM I-RTX lowered IL-6 to almost identical levels (25% and 26%, respectively). A possible explanation for this ceiling effect is that the total contribution of TRPV1 translates to a 25% increase in IL-6 release at elevated pressure, so that 1 μM I-RTX may be sufficient to inhibit this contribution of TRPV1. However, the ability of 1 μM and 10 μM I-RTX to inhibit the translocation of NFκB suggests that TRPV1 activity contributes to early signaling events related to the initiation of IL-6 transcription. These data suggest that TRPV1 in microglia, like cells of the cornea, lung, and epidermis, can modulate the stimulus-induced production of proinflammatory cytokines, including IL-6.97-99 However, the inability of I-RTX or ruthenium red to abolish pressure-induced increases in IL-6 release suggests that other cellular mechanisms contribute significantly to the IL-6 response. Furthermore, the fact that these antagonists had a greater effect on NFκB translocation than IL-6 release suggests that these mechanisms likely regulate IL-6 release at the protein rather than the transcriptional level.

Although TRP channels, including TRPV1, are activated by a wide range of stimuli, they are universally characterized by a strong Ca2+ conductance.100-103 To verify that exposure to elevated hydrostatic pressure induced Ca2+ conductance through TRPV1 in retinal microglia, we measured changes in the intracellular intensity of the Ca2+ dye Fluo-4 AM in microglia exposed to elevated pressure (Fig. 8). Our examination of Fluo-4 labeling revealed a global twofold increase in intensity over ambient levels. However, spatial mapping of Fluo-4 label revealed that the most dramatic change in Fluo-4 label occurred in microglial processes, which become more complex after exposure to elevated pressure in vivo.112,113 In fact, the antagonism of TRPV1 with I-RTX, which reduced Fluo-4 intensity by 26%, had the greatest impact on labeling in the processes. Consistent with the IL-6 and NFκB data, I-RTX did not reduce Fluo-4 intensity at elevated pressure to ambient levels, suggesting the involvement of other Ca2+ channels in pressure-induced changes. Although the Fluo-4 data present clear evidence for increased Ca2+ resulting from exposure to elevated pressure, Fluo-4 does not differentiate between Ca2+ released from intracellular stores and Ca2+ influx from extracellular sources. However, chelation of extracellular Ca2+ with EGTA provided the most dramatic effect on IL-6 release, suggesting that the influx of extracellular Ca2+ is likely to contribute significantly to increases in Ca2+. Of note, TRPV1-mediated increases in Fluo-4 label were evident after exposure to only 1 hour of elevated pressure. This was 7 hours before our previous observation of initial changes in IL-6 release and NFκB translocation.14 Like pressure-induced IL-6 release, pressure-induced elevation in Ca2+ was only modestly attenuated by the antagonism of TRPV1. Together with the observed effect of Ca2+ chelation and Ca2+ channel blockers in IL-6 release and NFκB translocation and our earlier findings, these data suggest TRPV1 Modulates NFκB and IL-6 with Pressure Ca2+ influx through TRPV1 may modulate pressure-induced IL-6 release and NFκB translocation. However, other mechanisms, which may also be Ca2+ dependent, play a significant role in these events. This is particularly likely at the protein level, where chelation and channel antagonism had the smallest impact on pressure-induced effects.

We should note here that the use of separate cultures for the measurement of Fluo-4 label at conditions of ambient and elevated pressure raises some possibilities for artifact. Specifically, no internal control is present for initial dye loading or dye leakage over time. We attempted to minimize these artifacts, while still using a high-affinity Ca2+ dye, in a number of ways. First, we examined each culture for equivalent dye loading before the start of the experiment. Any culture that did demonstrate qualitatively equivalent loading was excluded. Second, we used at least three and up to six culture plates per condition, for which the mean Fluo-4 intensity was determined and used in statistical comparisons. As such, a bias in dye loading that was not qualitatively identified would have to occur simultaneously in as many as six cultures. Similarly, our data required that the cultures maintained at elevated pressure had significantly slower rates of dye leakage than the cultures maintained at ambient pressure. For such an event to occur, elevated pressure must induce a statistically significant change in the membrane physiology of microglia compared with ambient pressure. Although we cannot rule out this possibility, the ability of I-RTX to reduce Fluo-4 signal at elevated pressure suggests that pressure-induced increases in Fluo-4 signal are the result of increased cytoplasmic Ca2+ rather than Fluo-4 retention.

In culture, TRPV1 was localized to processes and cell bodies, with evidence of perinuclear localization (Fig. 9). In adult retina, punctate immunolabel against TRPV1 was present in the processes of Iba1-positive microglia (Fig. 8A). The cell bodies of these microglia also exhibited diffuse Iba1 labeling for TRPV1. As described in other tissues, TRPV1 can be localized to the plasma membrane and the endoplasmic reticulum.90,91,114 The punctate labeling observed in microglial processes is consistent with localization to the plasma membrane. However, the more diffuse labeling in the cell body may also indicate localization to the endoplasmic reticulum. Therefore, these data support a potential role for TRPV1 in the influx of extracellular Ca2+ and its release from intracellular stores. Although these data do not shed light on the source of TRPV1-mediated Ca2+ modulation in response to elevated pressure, they do establish the viability of TRPV1 as a contributor to the responses of microglia in vivo.

Although culture systems have many advantages for the analysis of many biological functions, including cell-type specific analysis of cytokine release, there is no doubt that these systems also present limitations and confounding factors. In our study, the biomechanics of exposure to regulated hydrostatic pressure in vitro differs greatly from those involved in chronic, progressive exposure to variations in elevated ocular pressure in vivo. In addition, we cannot rule out the possibility that IL-6 production at elevated pressure is in response to other signaling factors, including IL-1α, IL-1β, TNFα, and IFNγ,115 rather than a direct response to elevated pressure. To produce a pressure stimulus that would be relevant to pressure stimuli in vivo, we based the design of our pressure chamber on those used to study the effect of hydrostatic pressure on cellular proliferation and membrane elasticity.116 In our studies, we carefully controlled pH and temperature and have also examined the dissolved O2 and CO2 content of the media.13,14 Others have shown that, when these factors are controlled or made negligible, the most likely sources of cellular perturbation are distortional strain, compression, and the gradient of liquid potential across the cell membrane.117-119 Which of these cellular events lead to IL-6 production and NFκB translocation is unclear. However, it is likely that RGCs in vivo, particularly
axons in the lamina cribosa, are likely to undergo similar strain and stretch in response to elevated IOP. Although the possibility remains that IL-6 is induced by other signaling factors rather than directly by pressure, the mechanistic components of the IL-6 pathway described in this study are active during exposure to elevated, but not ambient, pressure and lead to IL-6 release regardless of the exact nature of their induction.

In combination with our previous work, this study identifies Ca$^{2+}$ and TRPV1 as components of a signaling pathway that leads to pressure-induced release of IL-6 by microglia. Our data demonstrate that Ca$^{2+}$ modulation in response to elevated pressure occurs upstream of NFκB translocation and subsequent IL-6 production and release by retinal microglia. Furthermore, this Ca$^{2+}$ modulation occurs in part through the cation channel TRPV1. Although TRPV1 does not account for the entire Ca$^{2+}$ dependence of this signaling cascade, our data suggest that the contribution of TRPV1 is significant enough to inhibit the IL-6 response by approximately 25%. The identification of TRPV1 as a component of pressure-induced signaling distinguishes parallels between the pressure responses in retinal microglia and microglial activation in the brain and the stimulus-induced production of proinflammatory cytokines in other cell types.$^{97–100}$

Acknowledgments
The authors thank Philip Horner (University of Washington, Seattle, WA) for DBA/2 mouse tissue, Brian J. Carlson (Vanderbilt University Medical Center, Nashville, TN), and the Cell Imaging Core (Vanderbilt University Medical Center, Nashville, TN) for technical assistance.

References


TRPV1 Modulates NFkB and IL-6 with Pressure


